Skip to main content
OpenTrials
Completed

NCT Number: NCT02111876

Systematic Follow-up of Patients Surviving an Episode of Acute Hypercapnic Respiratory Failure in the ICU

There is currently no good description of patients surviving an episode of acute hypercapnic respiratory failure in the ICU. For instance, the prevalence of OSA and sleep hypoventilation in a stable clinical condition is not known in this population.

This prospective cohort describes the clinical profile, predictors of readmission (followed over a year), and the prevalence of sleep-related breathing disorders (polysomnography in a stable clinical condition 3 months after ICU discharge) in patients treated for an episode of acute hypercapnic respiratory failure in the ICU.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Hypercapnic Respiratory Failure Apnea Cardiovascular Diseases Chronic Disease Disease Attributes Dyssomnias Heart Diseases Heart Failure Lung Diseases Lung Diseases, Obstructive Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiration Disorders Respiratory Insufficiency Respiratory Tract Diseases Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Wake Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpitaux Universitaires de Genpve

Geneva, 1211, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • > 18 years Informed consent surviving an episode of acute hypercapnic respiratory failure

Exclusion criteria

  • iatrogenic hypercpania pregnant woman

Treatment and study plan

Primary outcomes

  1. Sleep apnea syndrome

    Time frame: at 2 month after ICU discharge

    Apnea-Hypopnea Index defined by polysomnography

  2. Sleep Hypoventilation

    Time frame: at 2 month after ICU discharge

    defined by AASM 2012 criteria with transcutaneous PtCO2 monitoring

Secondary outcomes

  1. Lung physiology ( obstructive or restrictive lung disease)

    Time frame: at week 2 after ICU discharge

    FEV1, VC, TLC, DLCO

  2. Inspiratory Muscle Strength

    Time frame: at week 2 after ICU discharge

    Sniff nasal maximal inspiratory pressure, Mouth inspiratory pressure

  3. Cardiac function

    Time frame: at week 2 after ICU discharge

    Systolic and diastolic cardiac function, pulmonary hypertension

  4. Hospital and ICU readmission rate

    Time frame: 1 year follow-up after ICu discharge

Sponsors and collaborators

Lead sponsor

Ligue Pulmonaire Genevoise

Other

Collaborators

  • University Hospital, Geneva

Registry information

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Apr 11, 2014
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.